HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q3 2018 13F Holders as of 30 Sep 2018

Type / Class
Equity / COM
Total 13F shares
13,267,532
Share change
-705,492
Total reported value
$66,965,000
Price per share
$5.05
Number of holders
54
Value change
-$2,427,351
Number of buys
34
Number of sells
20

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q3 2018

As of 30 Sep 2018, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 54 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 13,267,532 shares. The largest 10 holders included FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, Vanguard Group Inc, PUTNAM INVESTMENTS LLC, Private Wealth Partners, LLC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, Stonepine Capital Management, LLC, National Asset Management, Inc., PERKINS CAPITAL MANAGEMENT INC, and Russell Investments Group, Ltd.. This page lists 54 institutional shareholders reporting positions in this security for the Q3 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.